Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Payables (2016 - 2025)

Cytokinetics (CYTK) has disclosed Payables for 16 consecutive years, with $22.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Payables changed N/A to $22.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $22.3 million, a N/A change, with the full-year FY2025 number at $22.3 million, changed N/A from a year prior.
  • Payables was $22.3 million for Q4 2025 at Cytokinetics, up from $22.1 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $25.6 million in Q4 2022 to a low of $7.8 million in Q1 2021.
  • A 5-year average of $16.2 million and a median of $14.9 million in 2021 define the central range for Payables.
  • Peak YoY movement for Payables: soared 161.95% in 2021, then fell 25.29% in 2024.
  • Cytokinetics' Payables stood at $21.1 million in 2021, then grew by 21.45% to $25.6 million in 2022, then fell by 16.02% to $21.5 million in 2023, then crashed by 46.15% to $11.6 million in 2024, then skyrocketed by 92.88% to $22.3 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Payables are $22.3 million (Q4 2025), $22.1 million (Q3 2025), and $16.2 million (Q2 2025).